GENELUX CORPORATION Conversion of Stock, Shares Converted
GENELUX CORPORATION (GNLX) had Conversion of Stock, Shares Converted of 991.17 thousand shares as of 2023-01-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ConversionOfStockSharesConverted1 · last filed 2023-11-14
- 2023-01-30: Conversion of Stock, Shares Converted 991.17K shares.
| Period end | Conversion of Stock, Shares Converted |
|---|---|
| 2023-01-30 | 991.17K shares 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |